Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- HIV
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Dolutegravir (DTG) based dual antiretroviral therapy constitutes a paradigm shift from triple drug based therapy. Data outside clinical trials are scarce. This study evaluates the value of DTG/3TC in real life.
Dolutegravir (DTG) based dual antiretroviral therapy constitutes a paradigm shift from triple drug based therapy. Data outside clinical trials are scarce. This study evaluates the value of DTG/3TC in real life.
Tracking Information
- NCT #
- NCT04707326
- Collaborators
- Maasstad Hospital, Rotterdam
- MC Haaglanden, The Hague
- Catharina Ziekenhuis Eindhoven
- Elisabeth Hospital, Tilburg
- Rijnstate Hospital Arnhem
- Admiraal de Ruyter Hospital, Goes
- Spaarne Gasthuis, Haarlem
- MST, Enschede
- Investigators
- Not Provided
Get Well Soon